AVLN
AVLN clinical trials: Avalyn Pharma Inc.
Every trial on ClinicalTrials.gov where Avalyn Pharma Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
AVLN on the catalyst calendar · AVLN registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 31, 2031Sponsor estimate | NCT06951217An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)Avalyn Pharma Inc. · Progressive Pulmonary Fibrosis | AVLNLead | Phase 2 | Recruiting | Locked | Locked | Locked |
| Jun 2027Sponsor estimate | NCT06329401A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisAvalyn Pharma Inc. · Pulmonary Fibrosis | AVLNLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Dec 2026Sponsor estimate | NCT07194382AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFAvalyn Pharma Inc. · Idiopathic Pulmonary Fibrosis (IPF) | AVLNLead | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Dec 31, 2031Sponsor estimatePhase 2NCT06951217An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)Avalyn Pharma Inc. · Progressive Pulmonary FibrosisRecruitingAVLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT06329401A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisAvalyn Pharma Inc. · Pulmonary FibrosisActive, not recruitingAVLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT07194382AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFAvalyn Pharma Inc. · Idiopathic Pulmonary Fibrosis (IPF)RecruitingAVLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner